ArriVent's Nasdaq Debut Nabs $175M as Signs Indicate an Opening IPO Window

Retrieved on: 2024-01-26 16:48:04

Tags for this article:

Tyrosine kinase receptors

Epidermal growth factor receptor

Non-small-cell lung cancer

RET proto-oncogene

Amivantamab

Protein kinase inhibitor

Anaplastic lymphoma kinase

Lung cancer

ArriVent BioPharma

Click the tags to see associated articles and topics

ArriVent's Nasdaq Debut Nabs $175M as Signs Indicate an Opening IPO Window. View article details on hiswai:

Summary

The article describes ArriVent BioPharma's $175 million IPO, aimed at funding the development of furmonertinib, a tyrosine kinase inhibitor, for treating non-small-cell lung cancer with rare EGFR mutations, indicating a positive trend in the stock market for biotech firms.

Article found on: medcitynews.com

View Original Article